Novo Nordisk A/S (NVO)
48.66
+1.74
(+3.71%)
USD |
NYSE |
Aug 25, 16:00
48.32
-0.34
(-0.70%)
Pre-Market: 06:52
Novo Nordisk Market Cap : 162.81B for Aug. 25, 2026
Market Cap Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Market Cap Data
| Date | Value |
|---|---|
| August 25, 2026 | 162.81B |
| August 24, 2026 | 156.99B |
| August 21, 2026 | 156.39B |
| August 20, 2026 | 154.38B |
| August 19, 2026 | 155.52B |
| August 18, 2026 | 152.94B |
| August 17, 2026 | 150.16B |
| August 14, 2026 | 153.54B |
| August 13, 2026 | 156.32B |
| August 12, 2026 | 155.22B |
| August 11, 2026 | 157.83B |
| August 10, 2026 | 159.70B |
| August 07, 2026 | 158.13B |
| August 06, 2026 | 153.81B |
| August 05, 2026 | 148.99B |
| August 04, 2026 | 148.16B |
| August 03, 2026 | 157.56B |
| July 31, 2026 | 157.52B |
| July 30, 2026 | 172.68B |
| July 29, 2026 | 172.58B |
| July 28, 2026 | 170.51B |
| July 27, 2026 | 166.19B |
| July 24, 2026 | 163.18B |
| July 23, 2026 | 161.20B |
| July 22, 2026 | 161.24B |
| Date | Value |
|---|---|
| July 21, 2026 | 165.22B |
| July 20, 2026 | 165.99B |
| July 17, 2026 | 168.36B |
| July 16, 2026 | 172.25B |
| July 15, 2026 | 169.17B |
| July 14, 2026 | 164.18B |
| July 13, 2026 | 164.88B |
| July 10, 2026 | 165.55B |
| July 09, 2026 | 163.55B |
| July 08, 2026 | 163.58B |
| July 07, 2026 | 166.09B |
| July 06, 2026 | 164.82B |
| July 02, 2026 | 168.73B |
| July 01, 2026 | 163.18B |
| June 30, 2026 | 160.40B |
| June 29, 2026 | 162.86B |
| June 26, 2026 | 161.95B |
| June 25, 2026 | 160.51B |
| June 24, 2026 | 159.73B |
| June 23, 2026 | 159.76B |
| June 22, 2026 | 154.58B |
| June 18, 2026 | 145.51B |
| June 17, 2026 | 146.62B |
| June 16, 2026 | 146.73B |
| June 15, 2026 | 147.97B |
Market Capitalization Definition
Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding. This metric is important because it gives you an idea of the size of a company, and how the size has changed over time. When studying companies from a relative basis, it would make sense to compare companies that have a similar market capitalization because factors like market share, economies of scale, and business models would also be similar.
Market Cap Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Market Cap Benchmarks
| AstraZeneca PLC | 526.23B |
| Johnson & Johnson | 657.78B |
| Eli Lilly & Co. | 1.161T |
| Merck & Co., Inc. | 386.22B |
| Novartis AG | 292.85B |
Market Cap Related Metrics
| PE Ratio | 11.89 |
| PS Ratio | 4.204 |
| PEG Ratio | 0.9438 |
| Price to Book Value | 6.356 |
| Price to Free Cash Flow | 28.78 |
| Price | 48.66 |
| Earnings Yield | 8.41% |
| PEGY Ratio | 0.73 |
| Operating PE Ratio | 9.266 |
| Normalized PE Ratio | 11.43 |